Exploring the Spectrum of Virologic Failure in HIV

Target Audience

This activity is designed to educate infectious disease and other HIV-treating physicians (MDs), nurse practitioners (NPs), physician associates (PAs), and pharmacists.

Program Overview

Virologic failure (VF) for patients with HIV (PWH) is a significant concern when it occurs, as it may result in worse outcomes, reduced life expectancy, and increased HIV transmission. Clinicians must be prepared to identify the cause of VF and conduct resistance testing to identify patient susceptibility to antiretrovirals should they require a new antiretroviral therapy regimen (ART). There are multiple considerations when designing a new ART regimen, though the goal for all PWH is viral suppression. A small subset of patients are heavily treatment experienced and have multidrug resistance. Recent approvals of therapies specifically for this population have changed clinical practice and, though these patients are rare, clinicians must be fully prepared to identify subsequent ART regimens in challenging circumstances. In this interactive activity, Dr. Eric Daar will discuss principles of assessing VF, resistance testing, new treatment options for heavily treatment-experienced patients, and strategies for identifying subsequent ART regimens.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Utilize established guidelines and recommendations to effectively identify and evaluate patients experiencing virologic failure
2. Tailor subsequent ART regimens after virologic failure according to the patient’s resistance mutations and adherence needs
3. Incorporate approved therapies for heavily treatment-experienced patients when devising subsequent ART regimens

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Continuing Medical Education

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Reciprocity Statement

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Eric S. Daar, MD: Consulting Fees: Genentech, Gilead Sciences, Inc., Theratechnologies Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., ViiV Healthcare

The Integritas Communications planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.